

1 **Title: Antibodies targeting merozoites induce natural killer cell degranulation and**  
2 **interferon gamma secretion and are associated with immunity against malaria**

3

4 **Authors:** Dennis O. Odera<sup>1,2</sup>, James Tuju<sup>2</sup>, Kennedy Mwai<sup>2,3</sup>, Irene N. Nkumama<sup>1</sup>, Kristin  
5 Fürle<sup>1</sup>, Timothy Chege<sup>2</sup>, Rinter Kimathi<sup>2</sup>, Stefan Diel<sup>1</sup>, Fauzia K. Musasia<sup>1</sup>, Micha  
6 Rosenkranz<sup>1</sup>, Patricia Njuguna<sup>2</sup>, Mainga Hamaluba<sup>2</sup>, Melissa C. Kapulu<sup>2</sup>, Roland Frank<sup>1</sup>,  
7 Faith H. A. Osier<sup>1,2,4\*</sup>, and CHMI-SIKA Study Team<sup>#</sup>.

8 **Affiliations:**

9 <sup>1</sup>Centre of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

10 <sup>2</sup>Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute-  
11 Wellcome Trust Research Programme, Kilifi, Kenya

12 <sup>3</sup>Epidemiology and Biostatistics Division, School of Public Health, University of the  
13 Witwatersrand, Johannesburg, South Africa.

14 <sup>4</sup>IAVI Human Immunology Laboratory, Imperial College London, United Kingdom

15 <sup>#</sup>CHMI-SIKA Study Team members are listed in the supplementary information.

16 <sup>\*</sup>Corresponding author. [Fosier@iavi.org](mailto:Fosier@iavi.org) ; [Faith.osier@med.uni-heidelberg.de](mailto:Faith.osier@med.uni-heidelberg.de)

17

18

19

20

21

22

23

24

25

26

27

28

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

29 **Abstract:**

30 Natural killer cells are potent immune effectors that can be activated via antibody mediated  
31 Fc receptor engagement. Using multiparameter flow cytometry, we found that natural killer  
32 (NK) cells degranulate and release IFN $\gamma$  upon stimulation with antibody-opsonized  
33 *Plasmodium falciparum* merozoites. Antibody-dependent NK activity (Ab-NK) was largely  
34 strain-transcending and enhanced the inhibition of invasion into erythrocytes. Ab-NK was  
35 associated with the successful control of parasitemia following experimental malaria  
36 challenge in African adults. In an independent cohort study in children, Ab-NK increased  
37 with age, was boosted by concurrent falciparum infections and associated with a lower risk of  
38 clinical episodes of malaria. Nine of 14 vaccine candidates tested induced Ab-NK including  
39 some less well-studied antigens - P41, P113, MSP11, RHOPH3, and *Pf\_11363200*. These  
40 data highlight an important role for ab-NK in immunity against malaria and provide a new  
41 mechanism for the evaluation of vaccine candidates

42

43 **One Sentence Summary:** Antibody-dependent natural killer activation is induced by  
44 merozoites and associated with immunity against malaria

45 **Main Text:**

46

## 47 **INTRODUCTION**

48 The World Health Organization (WHO) recently recommended the widespread use of  
49 the RTS,S malaria vaccine in areas with moderate to high malaria transmission intensity<sup>1</sup>.

50 Whilst a major landmark as no other malaria vaccine has advanced this far, RTS,S is  
51 modestly efficacious and the protection it induces wanes rapidly<sup>2</sup>. Vaccine development for  
52 malaria remains an urgent priority. Repeated exposure to *P. falciparum* parasitemia under  
53 conditions of high transmission intensity results in long term immunity to clinical episodes of  
54 malaria<sup>3</sup>. Passive transfer experiments demonstrated the importance of antibodies in  
55 mediating protection<sup>4</sup>, but the precise mechanisms that underpin their actions are still under  
56 investigation and there are no universally accepted correlates of protection. Numerous studies  
57 focus on the Fab-dependent neutralization of parasites that occurs for instance when  
58 antibodies inhibit the invasion of erythrocytes by merozoites, with inconsistent results<sup>5</sup>.  
59 Antibody-dependent Fc-mediated interactions with effector cells are increasingly being  
60 recognized as important correlates of protection<sup>6-10</sup>

61

62 The abundance of natural killer (NK) cells in peripheral blood positions them as  
63 prime immune effectors<sup>11</sup>. They are known to target malignant or virus-infected cells through  
64 an array of germ-line encoded activation receptors<sup>12,13</sup>. They can also be activated by  
65 opsonized malaria parasites via the low-affinity immunoglobulin FcγRIIIa (CD16)<sup>7</sup>. Activation  
66 of NK cells leads to degranulation and the release of cytotoxic molecules like granzyme B, as  
67 well as the secretion of pro-inflammatory cytokines such as IFNγ<sup>14</sup>, with high Plasma levels  
68 of both associated with reduced parasitemia *in-vitro*<sup>15</sup> and in cohort studies<sup>16</sup>. Recent studies  
69 have shown that malaria-immune sera target *P. falciparum* infected erythrocytes via NK cells

70 leading to their destruction<sup>9,17</sup>. Merozoites may also be cleared in a similar fashion as  
71 antibodies to many merozoite antigens have been associated with protection against malaria  
72 and are considered as leading vaccine candidates<sup>18,19</sup>

73

74 We developed a novel antibody dependent natural killer cell assay (ab-NK) focused  
75 on *P. falciparum* merozoites. We demonstrate that anti-merozoite antibodies induce NK cell  
76 degranulation and IFN $\gamma$  production in a largely strain-transcending fashion and enhance  
77 invasion-inhibition *in-vitro*. We use a human malaria challenge study in adults and an  
78 independent prospective cohort study in children and demonstrate for the first time that ab-  
79 NK targeting merozoites is predictive of protection. We identify specific merozoite antigens  
80 that induce ab-NK and provide a novel mechanistic correlate to support the prioritization of  
81 vaccine candidates.

82

## 83 **RESULTS**

84

### 85 **Ab-NK activated following co-incubation with malaria-immune sera and merozoites**

86 We tested whether merozoite-specific antibodies activated NK cells that were freshly  
87 isolated (immediately following blood draw) from malaria-naïve donors. We measured the  
88 levels of the classical surface marker of NK cell degranulation (CD107a) and intracellular  
89 IFN $\gamma$  production. Activation was dependent on the presence of both malaria-immune sera and  
90 merozoites (Fig. 1A and B). Malaria-immune but not naïve sera activated NK cells in a dose-  
91 dependent fashion (Fig. S1A and B). We minimized assay variability by pooling NK cells  
92 from three independent donors in each experimental run (Fig. 1B). We validated the assay  
93 further using individual samples from malaria-exposed adults from Junju, Kenya, a region  
94 with moderate malaria transmission intensity (Fig. 1C & 1D).

95 As expected, ab-NK was significantly correlated with total IgG against merozoites,  
96 Spearman's  $R = 0.54$  and  $0.56$  for CD107a and IFN $\gamma$  respectively,  $P < 0.0001$  (Fig. 1E). This  
97 correlation was greater for the cytophilic IgG1 and IgG3 isotypes (CD107a  $R = 0.54$  &  $R =$   
98  $0.51$ ,  $P < 0.0001$ ), when compared with the non-cytophilic IgG2 and IgG4 (CD107a  $R = 0.47$   
99 &  $R = 0.39$ ,  $P < 0.0001$ ; Fig. S2 A and B).)

100


### 101 **Ab-NK is strain-transcending across African isolates of *P. falciparum***

102 We compared ab-NK against five *P. falciparum* parasite isolates using 20 samples  
103 from malaria-exposed adults from Junju. Four of the five isolates were long-term laboratory-  
104 cultured strains of diverse geographical origin; NF54, FCR3, and D10 from West Africa and  
105 Dd2 from South East Asia. The fifth was isolated in Kenya (East Africa), has recently been  
106 adapted to laboratory culture conditions and is subsequently referred to as the clinical isolate.  
107 The pairwise correlation coefficients for ab-NK degranulation were significant and high  
108 between the laboratory isolates of African origin (NF54, FCR3, D10; Spearman's  $R = 0.86$  to  
109  $0.92$ ,  $P < 0.001$ ) but lower when compared to the clinical isolate (Spearman's  $R = 0.45$  to  
110  $0.56$ ,  $P = 0.010$ , Fig. 1F). The latter may relate to the deletion of genes following long-term  
111 parasite culture<sup>20</sup>. The pairwise correlation coefficient between the SE Asian (Dd2) versus  
112 West African laboratory isolates (NF54, FCR3, D10) was markedly lower (Spearman's  $R =$   
113  $0.23$  to  $0.33$ ,  $P = 0.245$ , Fig. 1F), consistent with the distinct genomic architecture observed  
114 between parasite isolates from Asia and Africa<sup>21,22</sup>. Surprisingly, a significantly higher  
115 correlation was observed between the Kenyan clinical isolate and the SE Asian laboratory  
116 strain (Spearman's  $R = 0.70$ ,  $P < 0.001$ ) suggesting that these are more closely related.  
117 Similar results were observed for ab-NK IFN $\gamma$  production levels (Fig. S3)

118

### 119 **Ab-NK enhanced *P. falciparum* invasion inhibition**

120 *P. falciparum* merozoite invasion is a complex process that occurs within a narrow  
121 time window following schizont egress. To test whether ab-NK had an impact on merozoite  
122 invasion *in-vitro*, we used a modified standard invasion inhibition assay. Donor NK cells,  
123 uninfected red blood cells and freshly isolates merozoites were co-cultured in the presence or  
124 absence of antibodies. Malaria immunoglobulin (MIG) but not naïve antibodies inhibited  
125 parasite invasion. Interestingly, NK cells enhanced MIG-mediated invasion inhibition by  
126 48%. Anti-rAMA-1 (polyclonal antibodies raised in immunized rabbits) was included as a  
127 positive control for invasion inhibition (Fig. 1G).  
128



129

130 **Figure 1. Anti-merozoite antibodies activate NK cells.** (A) NK cell degranulation and IFN $\gamma$   
 131 production was measured by CD107a surface and intracellular staining respectively.

132 Merozoites were opsonized with a pool of malaria-immune or naïve plasma with

133 PHA/ionomycin included as a positive control. Data are from four independent experiments

134 and show the median with 95% confidence interval (95% CI); Kruskal-Wallis test. (B) Inter-  
135 assay variation was evaluated between days 1 versus 2 or 3. Pooled NK cells from 3  
136 independent donors were tested using the same 30 malaria-immune samples on 3 separate  
137 days.(C & D) *P. falciparum* merozoites opsonized with Plasma from individual malaria-  
138 exposed adults (red circles, n=21) or malaria-naïve plasma (blue circles, n=4) were co-  
139 incubated with donor NK cells. Representative flow plots of NK cells incubated with  
140 merozoites in the presence of the respective plasma are shown. An additional pool of hyper  
141 immune sera (PHIS, comprised of sera from Junju adults with high ELISA responses against  
142 the 3D7 schizont lysate; brown circles, n=4) was included as a positive control. Error bars  
143 represent 95% CI of the median values; Kruskal-Wallis test. (E) Pairwise correlation between  
144 the proportion of IFN $\gamma$  secreting or degranulating (CD107a+) NK cells activated by  
145 opsonized *P. falciparum* 3D7 merozoites and merozoite ELISA quantifying total IgG  
146 responses (n=142). (F) Spearman's correlation heatmap between the proportion of NK cells  
147 degranulating upon activation by opsonized merozoites from five *P. falciparum* strains of  
148 different geographical origins (n=20). (G) Viable merozoites were co-incubated with  
149 uninfected erythrocytes and test immunoglobulins in the presence or absence of donor NK  
150 cells. Data represent the median with 95% confidence intervals of three independent  
151 experiments.

152

153 **Table 1: Ab-NK predicts protection following malaria challenge**

---

	<b>IRR (95%CI)</b>	<b>P value</b>	<b>HR (95%CI)</b>	<b>P value</b>
CHMI Adults n=142				
CD107a+	<b>0.42(0.27-0.63)</b>	<0.001	<b>0.26(0.15-0.47)</b>	<0.001
IFN $\gamma$ +	<b>0.47(0.29-0.74)</b>	0.001	<b>0.19(0.09-0.41)</b>	<0.001

---

154

155 Incidence risk and hazard ratios (IRR, HR) with 95% confidence intervals (CI) estimated in

156 the modified Poisson (left panel) and Cox regression (right panel) models, respectively. All



157 multivariate models were adjusted for low levels of antimalarial drugs (below minimal  
158 inhibitory concentrations) and volunteer location of residence.

159


### 160 **Ab-NK is associated with protection following malaria challenge**

161 We next assessed ab-NK in samples collected on the day before challenge (C-1) in a  
162 controlled human malaria infection (CHMI) study in semi-immune Kenyan adults<sup>23</sup>. The  
163 study endpoints were clinical symptoms of malaria with any evidence of malaria parasites by  
164 blood film positivity or parasitemia > 500 parasites/ $\mu$ l, both of which warranted immediate  
165 treatment<sup>23</sup>. Treated volunteers were further classified into those who developed fever and  
166 those who did not (febrile versus non-febrile). Untreated volunteers were sub-classified based  
167 on parasite detection by PCR into PCR-ve and PCR+ve groups<sup>24</sup>.

168 We asked whether ab-NK before challenge was associated with protection.

169 Volunteers who were not treated (protected) had significantly higher levels of ab-NK cell  
170 degranulation and IFN $\gamma$  than those that were treated (unprotected). (Mann-Whitney t test,  $P <$   
171 0.00001; Fig. 2A and 2B). Among the treated volunteers, there was no difference in ab-NK  
172 between those that were febrile versus non-febrile. Likewise, in the untreated (protected) sub-  
173 group, there was no difference between those who were either PCR + or PCR-ve. (Fig. 2C).  
174 To test for associations with protection, we stratified ab-NK cell into high versus low sub-  
175 groups based on threshold values derived from maximally selected rank statistics<sup>25</sup>. For both  
176 degranulation and IFN $\gamma$  production, high ab-NK was associated with a significantly lower  
177 risk of treatment (incidence rate ratio 0.42 and 0.47 respectively,  $P <$  0.001; Table 1).  
178 Furthermore, the time to detection of clinical malaria (study endpoints) after the tenth day  
179 post-challenge was longest in volunteers with high compared to low levels of ab-NK, Cox  
180 regression hazard ratio (HR) 0.26 and 0.19 for degranulation and IFN $\gamma$  production  
181 respectively,  $P <$  0.001; Table 1, Fig 2D). These analyses were adjusted for the potential

182 confounding effects of low levels of lumefantrine (below the minimum inhibitory  
 183 concentrations) that were detected in the C-1 samples, and the geographical origin (location  
 184 of residence) of the volunteers.  
 185  
 186



187  
 188 **Figure 2. Antibody-mediated NK cell activity is associated with *in vivo* parasite growth.**


189 Comparison of ab-NK degranulation (A) and IFN $\gamma$  production (B) in treated (n=56) versus  
 190 non-treated (n=86) volunteers. Bars represent 95% CI of the median values; Mann-Whitney  
 191 test. (C) Sub-group analysis ab-NK degranulation for treated volunteers who either developed  
 192 fever (febrile n= 26) or did not (non-febrile n=30), and for untreated volunteers in whom  
 193 parasites were either detected by PCR (PCR+ve n=53) or remained negative (PCR-ve n=33).

194 Bars represent 95% CI of the median values; Kruskal-Wallis with Dunn's multiple  
195 comparison test. (D) Kaplan-Meier curves for the time to treatment for volunteers with a high  
196 (red) versus low(blue) ab-NK degranulation; log-rank test,  $P < 0.0001$   $n=142$ .

197

### 198 **Not all potential merozoite vaccine candidate antigens induce Ab-NK**

199 To distinguish distinct merozoite antigens that induce ab-NK from those that  
200 potentially did not, we developed a plate-based ab-NK assay utilizing recombinant antigens.  
201 We could thus detect and quantify antigen-specific ab-NK. We tested ab-NK for 14 *P.*  
202 *falciparum* merozoite surface-associated antigens identified as potential vaccine candidates in  
203 a previous study<sup>18</sup>. This analysis was conducted in a subset of CHMI samples with high ( $n=8$ )  
204 or low ( $n=2$ ) levels of ab-NK against whole merozoite extract. We found that antigen-specific  
205 ab-NK varied between antigens and individuals. We identified 8 potential merozoite targets  
206 of ab-NK out of the 14 tested (Fig. 3A). These included well-characterized vaccine  
207 candidates like AMA-1, MSP3 and MSP2 and less-well studied antigens like P41, P113,  
208 MSP11, RHOPH3, and *Pf*\_11363200 that have independently been associated with clinical  
209 protection<sup>14-16</sup>. (Fig. 3A). Responses against other leading blood stage vaccine candidates  
210 such as *Pf*Rh5 and EBA-175 had negligible ab-NK. Although we had pre-selected individuals  
211 with high ab-NK degranulation against whole merozoite extract, this did not always translate  
212 into high levels of antigen-specific ab-NK. This suggests that additional antigens that were  
213 not tested here contributed to the functional response against the whole merozoite (Fig. 3B).  
214 Additionally, we and others previously found that the breadth of the antibody response was  
215 associated with enhanced function<sup>19,28,29</sup>. In keeping with this, whole merozoite extract ab-  
216 NK cell degranulation and the breadth of antigen-specific ab-NK cell degranulation were  
217 strongly correlated (Fig. 3C and Fig 3D).



218  
 219 **Figure 3. Potential targets of antibodies that mediate ab-NK.** (A) Antigen-specific ab-NK  
 220 cell degranulation from a subset of CHMI individuals (n=10) against 14 unique recombinant  
 221 *P. falciparum* merozoite antigens. Blue line represents the cut-off value based on the mean  
 222 plus 3 standard deviations of the tag fragment (CD4 tag). Error bars represents 95% CI of the  
 223 median (Red line). (B) Heatmap of individual level antigen-specific ab-NK cell degranulation  
 224 from A. Each row represents a single CHMI participant and each column represents  
 225 responses to a single recombinant merozoite surface associated antigen. (C) Ab-NK cell  
 226 degranulation against whole merozoite extract was associated with the breadth of antigen-  
 227 specific recognition. Error bars represents 95% CI of the median (Red line) n= 142; Kruskal-  
 228 Wallis test. (D) The sum of antigen-specific ab-NK cell degranulation against 14 unique

229 recombinant merozoite antigens was correlated with NK cell degranulation against  
230 merozoites; Spearman correlation  $R = 0.80$ .

231 **Table 2: Junju cohort baseline characteristics**

	<b>&lt;5 years (151)</b>	<b>&gt;5 years (142)</b>	<b>0-12 years (293)</b>
Age category (n)			
Sex n(%positive)			
Male	<b>71 (47%)</b>	<b>72 (49%)</b>	<b>143 (48%)</b>
Malaria slide positive n(%)			
At cross sectional sampling	<b>28 (23%)</b>	<b>52 (36%)</b>	<b>80 (27%)</b>
Malaria episodes n (%positive)	<b>77 (51%)</b>	<b>45 (31%)</b>	<b>122 (41%)</b>
Ab-NK activity seropositive n (%)			
CD107a+ve	<b>99 (65%)</b>	<b>101 (71%)</b>	<b>200 (67%)</b>
IFN $\gamma$ +ve	<b>8 (6%)</b>	<b>12 (10%)</b>	<b>12 (10%)</b>

232

233

234 **Ab-NK increases with age following natural infections**


235 We next examined the acquisition of antibodies that mediated NK cell activity in 293  
236 samples collected from a longitudinal cohort study of children living in Junju, Kenya<sup>30</sup>. At  
237 the time of sampling, 67% of the children had antibodies that mediated NK cell degranulation  
238 while only 10% had antibodies that induced IFN $\gamma$  production, respectively (Table 2).  
239 Notably, we observed significantly lower ab-NK in children compared to adults living in the  
240 same location (Fig. S4A). Ab-NK increased with age (Fig. 4A; Fig. S4B). Additionally,  
241 children who were parasite slide positive at the time of sampling showed higher NK cell  
242 degranulation but not IFN $\gamma$  production than slide negative children, suggesting a boosting  
243 effect of ab-NK by active *P. falciparum* infection (Fig. 4B). Antibody responses against three  
244 malaria vaccine candidates (AMA-1, MSP2 and MSP3) had been measured in this cohort in a  
245 previous study<sup>30</sup>. Ab-NK in children was modestly correlated with antibody recognition of

246 AMA1 (CD107a+: R = 0.35 and IFN $\gamma$ +: R = 0.31), MSP2 (CD107a+: R = 0.28 and IFN $\gamma$ +: R  
247 = 0.35), and MSP3 (CD107a+: R = 0.25 and IFN $\gamma$ : R= 0.24; Spearman's R for all  
248 comparisons P< 0.0001; Fig. S4C). However, despite the modest correlation, the breadth of  
249 antibody recognition against the three merozoite antigens was associated with increased NK  
250 cell activity against the whole merozoite in children, again suggesting an additive effect when  
251 multiple targets are considered (Fig. 4C).

252

### 253 **Ab-NK is associated with protection against clinical episodes of malaria in children**

254 To date, no longitudinal cohort study has assessed the relationship between ab-NK  
255 against merozoites and protective immunity in children living in Kenya. We stratified ab-NK  
256 into high versus low categories based on derived thresholds<sup>25</sup> and fitted them to a Poisson  
257 regression analysis, adjusting for age and previous *P. falciparum* exposure as confounders<sup>6</sup>.  
258 We found that both degranulation and IFN $\gamma$  production were significantly associated with  
259 clinical protection CD107a (IRR: 0.34 (95% CI, 0.19-0.61); P < 0.000 and IFN $\gamma$ ; (IRR: 0.61  
260 (95% CI, 0.38-0.97); P < 0.040; Table 3). These findings were confirmed in a Cox regression  
261 analysis in which the time to the first malaria episode was analyzed as the outcome variable  
262 (log-rank test, P<0.0001; Fig. 4D).



263  
 264 **Figure 4. Antibody-mediated NK cell degranulation is associated with clinical**  
 265 **protection in a prospective cohort study in Kenyan children. (A)** Comparison of Ab-NK  
 266 in Junju children over or under 5 years of age. **(B)** Ab-NK response in children who had an  
 267 active *P. falciparum* infection compared to those without. Error bars represent 95% CI of the  
 268 median values; Mann-Whitney test (n=293). **(C)** Antibody-mediated NK cell degranulation is  
 269 correlated with the breadth of total IgG responses against recombinant MSP2, MSP3 and/or  
 270 AMA-1. Error bars represent 95% CI of the median values; Kruskal-Wallis test with Dunn's  
 271 multiple comparison test (n=293). **(D)** Ab-NK cell degranulation is associated with clinical  
 272 protection in children. NK cell degranulation responses were categorized as high or low  
 273 (blue) based on a threshold<sup>25</sup>; log-rank test, P= 0.001 (n=293). Each dot represents a technical  
 274 replicate.

275

276 **Table 3: Ab-NK is associated with a reduced risk of clinical malaria episodes in children**  
277 **from Junju, Kenya**

---

<b>Junju Children</b>	<b>IRR (95%CI)</b>	<b>P value</b>	<b>HR (95%CI)</b>	<b>P value</b>
0-12 years (n=293)				
CD107a+	0.34(0.19-0.61)	0.000	0.26(0.13-0.52)	0.000
IFN $\gamma$ +	0.61(0.38-0.97)	0.038	0.54(0.30-0.97)	0.040

---

278  
279 Ab-NK cell degranulation and IFN $\gamma$  production were fitted to modified Poisson regression  
280 models. Results are presented as incidence risk ratios (IRR) or hazard ratios (HR) with 95%  
281 confidence interval (CI). P-values >0.05 were considered significant. All models were  
282 adjusted for age and previous *P. falciparum* exposure as confounders.

283

284 **DISCUSSION**

285 Defining the mechanisms that underpin the potent efficacy of malaria  
286 immunoglobulin observed in passive transfer experiments provides a strong evidence-base  
287 for rational vaccine development. We report for the first time that anti-merozoite antibodies  
288 engage Fc receptors on natural killer cells, thereby unleashing potent anti-parasite effector  
289 activity. Ab-NK was associated with clinical protection in two independent studies and  
290 induced responses against multiple parasite strains, including a recently adapted clinical  
291 isolate. Additionally, we identify a subset of merozoite antigens that induce ab-NK and show  
292 that the breadth of antigen-specific ab-NK mirrors that quantified against merozoites. Our  
293 data augment the accumulating body of evidence that targeting combinations of antigens may  
294 be instrumental for malaria vaccine design<sup>18,19,29,31-35</sup>. We also provide a new mechanism for  
295 the prioritization and subsequent evaluation of vaccine candidates.

296 Although several immune mechanisms have been proposed as correlates of  
297 protection, none have focused on Fc-antibody-dependent targeting of merozoites by natural  
298 killer cells. The growth inhibition assay (GIA) is considered the gold standard for the



299 assessment of antibody function and is thought to assess a combination of invasion-  
300 inhibition, growth inhibition and possibly merozoite egress<sup>36-39</sup>. Unfortunately, it does not  
301 reliably predict protection. Other studies have investigated the role of complement<sup>7</sup>,  
302 monocytes<sup>6</sup> and neutrophils<sup>8</sup>, marking the increasing importance of Fc-mediated function<sup>10</sup>,  
303 with promising results that need further validation in additional studies. Importantly, our  
304 unique challenge study allowed us to overcome many of the limitations of cohort studies that  
305 often lead to conflicting results when any functional correlate of protection is considered. The  
306 timing and intensity of our experimental parasite challenge was accurately defined, and close  
307 monitoring for clinical symptoms and parasite multiplication rates was feasible because  
308 volunteers were hosted at a single location for the duration of the study. We included adults  
309 from a single East African country to minimize genetic variability and pre-selected  
310 individuals with a varied range of previous malaria exposure to allow us to explore its'  
311 impact on the clinical outcome. Under these stringent conditions, we observed a strong and  
312 significant correlation between ab-NK and protection. We found similar results in an  
313 independent study, involving only children, and that utilized an entirely different design in  
314 which malaria infections occurred naturally under real-life conditions.

315 Natural killer cells have been extensively studied for their role in the early defense  
316 against viral infections and cancers. Additionally, the modulation of their function underpins  
317 an array of contemporary immunotherapeutic agents<sup>40,41</sup>. Our study capitalizes on the unique  
318 ability of the FcγRIIIa (CD16) to induce NK cell in response to antibody-coated targets,  
319 without engaging other activating or inhibitory receptors<sup>42</sup>. The potential impact of this  
320 mechanism on vaccines against infectious diseases is relatively understudied. Recently, a  
321 human monoclonal antibody (mAb) against a conserved region of the haemagglutinin (HA)  
322 protein, was shown to not only potently neutralize a broad range of influenza viruses, but also

323 to mediate ADCC<sup>43</sup>. In HIV, evidence that ADCC-mediating antibodies complement  
324 neutralizing functions is accumulating<sup>44,45</sup>.

325 In malaria, natural killer cells were identified as part of the early innate immune  
326 response, through the production of IFN $\gamma$  and soluble granzymes<sup>14</sup>. Although recent data  
327 suggest that they can acquire a memory-like “adaptive” phenotype following repeated  
328 exposure with malaria<sup>17,46</sup>, our study utilized malaria-naïve NK cells to interrogate their  
329 interaction with anti-merozoite antibodies. As shown for malaria antigens exposed on the  
330 surface of infected red cells<sup>9,46,47</sup> antibodies against merozoites induce Fc-receptor dependent  
331 NK activation. In our studies, antibodies inducing ab-NK increased with age, were boosted  
332 by recent malaria infections and were strongly predictive of immunity. Furthermore, our  
333 antigen-specific ab-NK assay provides novel insights on individual merozoite antigens that  
334 induce functional antibodies and could guide rational vaccine design.

335 The detection of functional activity against a diverse panel of parasite strains is  
336 noteworthy and a vitally important consideration when new assays and vaccine candidates are  
337 assessed<sup>5,35</sup>. Previous studies investigating antibody-dependent NK effector function in *P.*  
338 *falciparum* focused on a single laboratory strain<sup>9,17,46,47</sup>. We found that ab-NK responses  
339 against merozoites from diverse *P. falciparum* strains originating in Africa were strongly  
340 correlated. Although this suggests that some of these antibodies target conserved epitopes,  
341 further confirmation at the antigen and indeed epitope level is needed. Interestingly, the  
342 weaker correlations between the African laboratory versus clinical isolate indicate that some  
343 antibodies do target polymorphic epitopes. In influenza, ADCC-mediating antibodies target  
344 conserved epitopes in the HA protein<sup>48</sup>, raising the exciting possibility of broadly protective  
345 universal influenza vaccines.

346 We developed a high-throughput plate-based antigen-specific ab-NK cell assay<sup>49</sup> to  
347 home-in on specific merozoite antigens targeted by ab-NK. We tested a pragmatic panel of

348 merozoite antigens that were available to us from previous studies in a subset of samples  
349 from adults<sup>50</sup>. We observed high inter-individual variation and unique ab-NK antigen-specific  
350 reactivity profiles in each sample. This was not surprising given the heterogeneity of antibody  
351 responses against malaria antigens that we, and others, have previously reported<sup>18,51</sup>.  
352 Interestingly, leading vaccine antigens known to induce invasion-inhibitory antibodies such  
353 as AMA1<sup>52</sup>, or Fc-dependent activity in phagocytosis such as MSP3<sup>6</sup>, were also targeted by  
354 ab-NK in some, but not all individuals. Less-well studied vaccine candidates such as Pf113  
355 and P41 also induced ab-NK in a proportion of individuals. Notably, some individuals  
356 elicited high levels of ab-NK against the whole merozoite, but not against a broad range of  
357 tested antigens. Further dissection of antigen and epitope specificity is warranted and may be  
358 instructive for vaccine design.

359 Previous studies have demonstrated that the breadth of the antibody response against  
360 selected parasite antigens is an important predictor of protection against malaria<sup>18,19,29,31–35,53</sup>.  
361 The breadth of antibody reactivity against the 14 *P. falciparum* antigens tested in the current  
362 study was associated with higher ab-NK against the whole merozoite. This mirrors  
363 observations from other functional studies in which the breadth of the antigen-specific  
364 functional Fc-antibody dependent response was correlated with protection<sup>18,19</sup>. These data  
365 suggest that an effective malaria vaccine modelled on naturally acquired immunity may not  
366 only need to incorporate multiple antigens, but also induce antibodies that trigger diverse  
367 effector functional activity. The influenza example is a case in point; a multifunctional human  
368 mAb was identified that simultaneously neutralizes virus and induces ADCC<sup>43</sup>.

369 We identify antibody-mediated NK cell activity targeting merozoites as a strong  
370 predictor of naturally acquired immunity against *P. falciparum* malaria. Our antigen-specific  
371 assay facilitates throughput and will galvanize additional studies focusing on specific vaccine

372 candidates. Further dissection of ab-NK inducing antibodies at the epitope level may reveal  
373 important signatures for universal vaccine design.

374

## 375 **MATERIALS AND METHODS**

### 376 **Study design and samples**

#### 377 Controlled human malaria infection (CHMI) study

378 The study design and details of the CHMI study have been described previously<sup>54</sup>. Briefly, a  
379 dose of 3200 infectious, cryopreserved *P. falciparum* NF54 sporozoites (Sanaria PfSPZ) was  
380 administered intravenously to 161 consenting Kenyan adults (18-45 years) with varying  
381 degrees of prior exposure to malaria (based on ELISA responses to crude *P. falciparum* 3D7  
382 schizont lysate). Testing for parasitemia was conducted twice daily from day 7 to 14; and  
383 once from day 15 to 21 days post-challenge by qPCR. Subjects were treated either when they  
384 had more than 500 Pf/ $\mu$ L, exhibited clinical symptoms and had any parasitemia or at the end  
385 of the active follow up period on day 21. Data from 19 individuals were excluded due to  
386 detectable drug levels<sup>54</sup> (Fig. S6). We analyzed 142 plasma samples collected one day before  
387 the challenge (C-1) to test whether ab-NK was associated with a lower risk of clinical malaria  
388 or parasitemia > 500 Pf/ $\mu$ L.

389

#### 390 Longitudinal study: Junju cohort

391 The Junju cohort was established in 2005 as part of a malaria vaccine trial<sup>55</sup>, and participants  
392 have been followed up since then. Briefly, we analyzed 304 plasma sample collected at the  
393 beginning of the malaria transmission season in May 2008 from children aged between 0-12  
394 years and resident in Junju village, Kilifi County. The *Plasmodium falciparum* parasite rate  
395 standardized to the age group 2–10 years (PfPR<sub>2-10</sub>) was 29% at the time of sampling. Active  
396 follow-up involved weekly visits to participants homes where a questionnaire for clinical

397 symptoms was administered and temperature was recorded. In addition, study personnel were  
398 resident in the village and were contacted by caregivers contacted at any time if the children  
399 were unwell. A clinical malaria episode was defined either as a temperature of  $>37.5^{\circ}\text{C}$  plus  
400 any parasitemia for children under 1 year, or a temperature of  $>37.5^{\circ}\text{C}$  plus a parasitemia of  
401  $>2500$  *Pf*/ $\mu\text{L}$  for children older than 1 year<sup>56</sup>. We analyzed data spanning the malaria  
402 transmission season of approximately 6 months duration. Independent samples collected from  
403 adults in Junju (n = 40) were used to establish and optimize the ab-NK cell assay. A pool of  
404 hyper-immune sera collected from malaria-exposed adults (PHIS) from Kilifi, Kenya and a  
405 commercial Malaria Immune Globulin<sup>57</sup> (MIG) were used for validation experiments and as  
406 positive controls.

407

#### 408 **Cultivation, purification and quantification of viable *P. falciparum* merozoites**

409 *P. falciparum* laboratory adapted strains of West African (NF54, FCR3, D10) and SE Asian  
410 origin (Dd2), as well as a recently adapted clinical isolate from Kilifi, Kenya (P0000072)  
411 were cultured in RPMI-1640 media supplemented with 0.5% Albumax, 25 $\mu\text{g}/\text{mL}$   
412 gentamycin, 50 $\mu\text{g}/\text{mL}$  Hypoxanthine, 2mM L-glutamine and 25mM HEPES buffer. Cultures  
413 were maintained at 2% parasitemia with O-positive erythrocytes obtained from malaria-naïve  
414 donors (less than 2 weeks old). Free viable merozoites were isolated as previously described  
415 <sup>58</sup>. Briefly, *P. falciparum* cultures were allowed to attain 10-15% parasitemia and  
416 synchronized at the ring stage using 5% sorbitol. After 24 hours, late stage pigmented  
417 trophozoites were harvested by Magnetic Activated Cell Sorting (MACS) column purification  
418 as per the manufacturer's instructions (Miltenyibiotec), attaining trophozoite purifications of  
419 80-95%. The enriched trophozoites were put back in culture and allowed to develop until  
420 they began to undergo schizogony (segmented nuclei) whereby 1mM of a protease inhibitor  
421 (E64; SIGMA) was added to allow maturation into late schizonts but inhibit rupture. Mature

422 schizonts were collected and passed through a 1.2µm microfilter previously blocked in 1%  
423 casein in PBS for 10 minutes to release free viable merozoites. These were either  
424 immediately used in the IIA-ADCC assay or washed twice in PBS, quantified and stored at -  
425 80°C until needed. The relative concentration of the stored merozoites was determined using  
426 CountBright™ absolute counting beads as per the manufacturer's instructions. In brief, 50µL  
427 of counting beads with a known concentration was mixed with a known volume of  
428 merozoites stained with 100µL 1X SYBR® dye for 15 minutes at 24°C and acquired on a BD  
429 FACSCaliburII flow cytometer. Merozoites were resuspended in 1XPBS at a working  
430 concentration of  $5 \times 10^7$  merozoites/mL and stored at -80°C.

431

#### 432 **Recombinant expression of *P. falciparum* merozoite antigens**

433 The recombinant merozoite antigens were expressed in-house as previously described<sup>50</sup>. In  
434 brief, Expi293F cells (Invitrogen) were cultured to a density of  $2.0 \times 10^6$  cells/mL and  
435 transfected with expression vectors using the Expifectamine 293 transfection reagent  
436 (Invitrogen). Cells were then incubated at 37°C with 8% CO<sub>2</sub> in an orbital shaker at 125 rpm.  
437 Culture supernatants were harvested 6 days post-transfection and proteins purified using Ni-  
438 NTA purification columns (Invitrogen).

439

#### 440 **ELISA**

441 A standardized ELISA protocol was performed as published<sup>16,29,30,59</sup>. In brief, a pre-  
442 determined concentration of recombinant *P. falciparum* recombinant antigens (30ng/well) or  
443 free whole merozoites ( $5 \times 10^5$  merozoites/well) were coated overnight at 4°C. The plates were  
444 washed with PBS followed by blocking with 1% casein in PBS (Invitrogen) for 2 hours at  
445 37°C. After four washes, 50µL of test plasma sample diluted 1:20 in PBS was added to the  
446 plates in duplicate and incubated for 1 hour at 37°C, followed by four additional washes. The

447 plates were incubated for 1 hour at 37°C with 100µL of secondary anti-human IgG, IgG1,  
448 IgG2, IgG3 or IgG4 (Invitrogen) antibodies used to determine total IgG or IgG isotype  
449 specific antibody responses, respectively. Plates were washed and 100µL of OPD substrate  
450 (Invitrogen) in PBS was added and incubated for 20 minutes for color development. The  
451 reaction was stopped with 1M hydrochloric acid solution (Sigma) and optical density  
452 quantified at 492nm. Plasma samples from a pool of hyper immune adults (PHIS) and a pool  
453 of malaria-naïve German donors were used as positive and negative controls respectively.  
454 Samples were considered seropositive if they had an optical density higher than the mean  
455 plus 3 standard deviation of the naïve controls.

456

#### 457 **NK cell isolation**

458 Venous blood was collected from healthy malaria-naïve donors and PBMCs were  
459 subsequently isolated within 4 hours of collection using density gradient separation on a  
460 histopaque (1077g/dL) monolayer. The PBMCs were washed twice in PBS, assessed for  
461 viability using trypan blue exclusion and resuspended in cold RPMI-1640 media  
462 supplemented with 10% fetal calf serum (Sigma) at a final concentration of  $1.0 \times 10^7$  cells/mL.  
463 The NK cells were isolated from the PBMCs by depleting non-NK cells lymphocytes  
464 (negative selection) using an NK isolation kit as per the manufacturer's instructions  
465 (Miltenyibiotec). Briefly, 20µL of a cocktail of monoclonal antibodies was added to  $1.0 \times 10^7$   
466 PBMCs and incubated for 30 minutes followed by 30 minutes incubation with 40µL of  
467 microbeads at 4°C. The PBMC mixture was then passed through a MACs column followed  
468 by 5ml of cold RPMI-1640 before collecting NK cells in the flow-through. The enriched NK  
469 cell mixture was washed, resuspended in fresh NK cell medium, (RPMI-1640, 10% FCS, 1%  
470 Penicillin/streptomycin and 2mM L-glutamine) and used on the same day. The NK cell  
471 isolation efficiency and cell purity (> 90%) was confirmed by flow cytometry (Fig. S1D).



472

473 **NK cell degranulation and intracellular cytokine assay**

474 Whole merozoites ( $4.5 \times 10^6$  merozoites/well) or recombinant *P. falciparum* antigens  
475 (30ng/mL) were coated overnight in 96 well-culture plates at 4°C. The wells were washed  
476 with PBS and blocked for 2 hours at 37°C with 1% casein in PBS. The coated plates were  
477 opsonized with heat-inactivated, pre-diluted (1:20) plasma samples for 5 hours at 37°C.  
478 Freshly isolated NK cells were added into each well ( $2.0 \times 10^3$  NK cell/well). Anti-human  
479 CD107a PE (1:50), brefeldin A and monensin (5µg/mL) were added and the plate was  
480 incubated for 18 hours at 37 °C in 5% CO<sub>2</sub>. The NK cells were washed, centrifuged at 1500  
481 rpm for 5 minutes and resuspended in FACS buffer (PBS, 1% BSA, 1mM EDTA and 0.1%  
482 sodium azide). Their viability was assessed by staining with a fixable viability dye eFluor  
483 <sup>TM</sup>520 for 10 minutes at 4°C. The temperature was maintained at 4°C for all subsequent steps.  
484 A cocktail of anti-human monoclonal antibodies comprising of anti-CD56 APC, anti-CD3  
485 PE-Cy5 and anti-CD16 APC-Cy7, was used to stain the corresponding NK cell surface  
486 markers for 30 minutes. The cells were subsequently washed twice with FACS buffer; fixed  
487 with CELL fix (BD) for 10 minutes and permeabilized with a permeabilization buffer (BD)  
488 for 10 minutes. The permeabilized NK cells were stained intracellularly with anti-human  
489 IFN $\gamma$  PE-Cy7 for 1 hour in the dark. Finally, the NK cells were washed thrice in  
490 permeabilization buffer, resuspended in FACS buffer and stored at 4°C awaiting acquisition.  
491 Controls wells included: 1) un-opsonized merozoites, 2) merozoites opsonized with malaria-  
492 naïve plasma, 3) merozoites opsonized with PHIS, 4) merozoites incubated with PBS only,  
493 and 5) NK cells incubated with 1ng/mL of Phytohemagglutinin (PHA) and 1ug/mL  
494 ionomycin (nonspecific NK cell stimulants). Acquisition was performed on the BD  
495 FACSCaliburII high-throughput system in a 96-well plate format using FACSDiva®. Data  
496 analysis was performed using FlowJo V10.



497 **Modified invasion inhibition assay (IIA-ADCC)**

498 Approximately 20,000 NK cells/well, uninfected erythrocytes and antibodies from malaria-  
499 naïve or malaria-exposed adults were resuspended in *P. falciparum* culture media at a final  
500 hematocrit of 0.5%/well) in a 96-well plate format. Synchronized schizonts (500µL pellet )  
501 from *P. falciparum* strain NF54 was resuspended in 2500µL *P. falciparum* culture media and  
502 filtered through a 1.2µM membrane to release viable merozoites<sup>58</sup> and immediately added  
503 into each well (40µL/well). The culture plate was incubated in a shaking incubator (50 rpm)  
504 for 30 minutes at 37°C to promote invasion. Purified polyclonal anti-rAMA-1(1.5ng/well),  
505 pooled malaria-naïve immunoglobulin (1.5ng/well) and a commercial anti-malaria  
506 immunoglobulin, MIG (1.5ng/well) were tested. After the 30 minutes co-incubation of  
507 merozoites, antibodies and NK cells; unbound antibodies and free merozoites were removed  
508 by washing the culture twice in fresh *P. falciparum* culture media. Subsequently, NK cells  
509 were removed using density gradient separation by gently adding 80µL/well of histopaque  
510 (1077g/dl) and spinning at 1800 rpm for 15 minutes without brakes. The culture was then  
511 washed twice, resuspended in *P. falciparum* culture media (100µL/well) and maintained for  
512 an additional 30 hours at 37°C. At the end of incubation, parasites were stained using the  
513 SYBR dye and enumerated by flow cytometry. Invasion inhibition was calculated against the  
514 proportion of the parasitemia recorded in the reference wells (test well without any antibody  
515 or NK cells)

516

517 **Flow analysis**

518 Flow data was analyzed using FlowJo V10.1 (TreeStar). For the analysis of phenotypic data,  
519 positive gates for CD56, CD16 and CD3 were used to define NK cells. For the antibody  
520 mediated functional data, positive gates for intracellular cytokine production and  
521 degranulation were included with the resulting proportion of each subset tabulated.

## 522 **Statistical Analysis**

523 Data was analyzed using Prism 8.07 (GraphPad) or Stata (version 14). The Mann Whitney U  
524 test was used to compare medians between distinct pairs. The Kruskal-Wallis test was use to  
525 compare more than two groups and supplemented by Dunn's test for multiple comparisons. A  
526 nonparametric Spearmans' correlation was used to estimate the strength of pairwise  
527 correlations. The threshold level (analytical cutoff) above which ab-NK was associated with  
528 protection was derived using maximally selected rank statistics<sup>25</sup>. The responses were  
529 grouped into two groups (high and low). Associations with protection were assessed in both  
530 studies using the modified Poisson and Cox regression models<sup>6,29,30</sup>. Potential confounders  
531 were adjusted to the respective models and included; detectable levels of lumefantrine in the  
532 sample collected one day prior to challenge and the location of residence.in the CHMI study.  
533 For the Junju cohort, we adjusted for, age and schizont reactivity as a proxy for previous  
534 exposure.

## 535 **Supplementary Materials**

536 Fig. S1. Optimization of novel ab-NK assay  
537 Fig. S2. Ab-NK activity is correlated with anti-merozoite antibody binding  
538 Fig. S3. Ab-NK activity mediates strain transcending responses  
539 Fig. S4. Antibody mediated NK cell activity in children.  
540 Fig. S5. Flow cytometry gating strategy  
541 Members of the CHMI-SIKA study team.

542

543 **Acknowledgments:** We thank all the study volunteers who participated in the CHMI-SIKA  
544 and Junju study. We are thankful to the larger study teams in Kilifi responsible for  
545 recruitment, data entry, sample processing and storage. Additionally, we appreciate all our  
546 malaria-naïve donors who provided us with fresh PBMCs.

547

548 **Funding:** We are grateful to all the study volunteers who have participated in the CHMI-  
549 SIKA study. We are also very grateful to the study teams at the study sites in Kilifi and  
550 Ahero, the collaborating teams at Sanaria, the study investigators, and all the clinical and  
551 laboratory teams. The CHMI-SIKA study was supported by a Wellcome Trust grant (107499)  
552 and sponsored by the University of Oxford. This work was supported by a Sofja  
553 Kovalevskaja Award from the Alexander von Humboldt Foundation (3.2 - 1184811 - KEN -  
554 SKP) and an EDCTP Senior Fellowship (TMA 2015 SF1001) which is part of the EDCTP2  
555 programme supported by the European Union awarded to F.H.A.O. F.K.M. was supported by  
556 a scholarship from the German Academic Exchange Service (DAAD), Funding Programme  
557 57214224, ST-32-PKZ 91608705. This research was commissioned in part by the National  
558 Institute for Health Research (NIHR) Global Health Research programme (16/136/33) using  
559 UK aid from the UK Government. K.M. was supported by the NIHR Global Health Research  
560 Unit Tackling Infections to Benefit Africa (TIBA). The views expressed in this publication  
561 are those of the author(s) and not necessarily those of the NIHR or the Department of Health  
562 and Social Care.

563

564

565 **Author contributions:** DOO and FHAO conceived and designed the experiments. DOO,  
566 FHAO, RF and KM performed the analysis. JT, TC and RC contributed recombinant  
567 antigens. DOO, INN, KF, SD and MR performed experiments. FHAO, PN, MH, MCK,  
568 provided the clinical samples. DOO, RF and FHAO wrote and edited the paper. All authors  
569 contributed to revision of the manuscript.

570

571 **Ethical Statement:**

572 The CHMI study was conducted at the KEMRI Wellcome Trust Research Programme in  
573 Kilifi, Kenya with ethical approval from the KEMRI Scientific and Ethics Review Unit  
574 (KEMRI//SERU/CGMR-C/029/3190) and the University of Oxford Tropical Research Ethics  
575 Committee (OxTREC 2-16). All participants gave written informed consent. The study was

576 registered on ClinicalTrials.gov (NCT02739763), conducted based on good clinical practice  
577 (GCP), and under the principles of the Declaration of Helsinki.

578 The Junju cohort, were originally recruited in 2005 and has been followed up, for clinical  
579 episodes of malaria<sup>55</sup>. In this study we used samples collected in 2008. Ethical approval for  
580 the Junju study was provided by the Kenyan National and Scientific Ethics Review  
581 Committee protocol number 3149.

582

583 **Competing Interests:** All authors declare no conflict of interest

584

585 **Data and material availability:** The study protocol and outcomes are published<sup>23</sup>.  
586 Additional original data that support the findings of this study are available from the data  
587 governance committee at KWTRP upon reasonable request; [dgc@kemri-wellcome.org](mailto:dgc@kemri-wellcome.org)

588

589

## 590 **References**

- 591 1. WHO Malaria fact sheets. WHO malaria Fact sheets. *WHO [online]*,  
592 <https://www.who.int/news-room/fact-sheets/detail/malaria> [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/malaria)  
593 [room/fact-sheets/detail/malaria](https://www.who.int/news-room/fact-sheets/detail/malaria) (2021).
- 594 2. RTSs, P. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster  
595 dose in infants and children in Africa: Final results of a phase 3, individually  
596 randomised, controlled trial. *Lancet* **386**, 31–45 (2015).
- 597 3. Marsh, K. & Kinyanjui, S. Immune effector mechanisms in malaria. *Parasite*  
598 *Immunol.* **28**, 51–60 (2006).
- 599 4. COHEN, S., MCGREGOR, I. A. & CARRINGTON, S. Gamma-globulin and acquired  
600 immunity to human malaria. *Nature* **192**, 733–737 (1961).
- 601 5. Duncan, C. J. A., Hill, A. V. S. & Ellis, R. D. Can growth inhibition assays (GIA)  
602 predict blood-stage malaria vaccine efficacy. *Hum. Vaccin. Immunother.* **8**, 706–714  
603 (2012).
- 604 6. Osier, F. H. *et al.* Opsonic phagocytosis of Plasmodium falciparum merozoites:  
605 mechanism in human immunity and a correlate of protection against malaria. *BMC*  
606 *Med.* **12**, 108 (2014).
- 607 7. Boyle, M. J. *et al.* Human antibodies fix complement to inhibit Plasmodium  
608 falciparum invasion of erythrocytes and are associated with protection against malaria.  
609 *Immunity* **42**, 580–590 (2015).

- 610 8. Joos, C. *et al.* Clinical protection from falciparum malaria correlates with neutrophil  
611 respiratory bursts induced by merozoites opsonized with human serum antibodies.  
612 *PLoS One* **5**, e9871 (2010).
- 613 9. Arora, G. *et al.* NK cells inhibit plasmodium falciparum growth in red blood cells via  
614 antibody-dependent cellular cytotoxicity. *Elife* **7**, 1–20 (2018).
- 615 10. Feng, G. *et al.* Mechanisms and targets of Fcγ-receptor mediated immunity to malaria  
616 sporozoites. *Nat. Commun.* **12**, (2021).
- 617 11. Björkström, N. K., Ljunggren, H. G. & Michaëlsson, J. Emerging insights into natural  
618 killer cells in human peripheral tissues. *Nat. Rev. Immunol.* **16**, 310–320 (2016).
- 619 12. Vivier, E. *et al.* Innate or adaptive immunity? The example of natural killer cells.  
620 *Science* **331**, 44–49 (2011).
- 621 13. Kerry S. Campbell, J. H. NK cell biology: An update and future directions. *Am. Acad.*  
622 *Allergy, Asthma Immunol.* **132**, 536–544 (2013).
- 623 14. Wolf, A.-S., Sherratt, S. & Riley, E. M. NK Cells: Uncertain Allies against Malaria.  
624 *Front. Immunol.* **8**, 212 (2017).
- 625 15. Kapelski, S., De Almeida, M., Fischer, R., Barth, S. & Fendel, R. Antimalarial activity  
626 of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion  
627 protein. *Antimicrob. Agents Chemother.* **59**, 669–672 (2015).
- 628 16. D’Ombrain, M. C. *et al.* Association of early interferon-gamma production with  
629 immunity to clinical malaria: a longitudinal study among Papua New Guinean  
630 children. *Clin. Infect. Dis.* **47**, 1380–1387 (2008).
- 631 17. Hart, G. T. *et al.* Adaptive NK cells in people exposed to Plasmodium falciparum  
632 correlate with protection from malaria. *J. Exp. Med.* **216**, 1280–1290 (2019).
- 633 18. Osier, F. H. *et al.* New antigens for a multicomponent blood-stage malaria vaccine.  
634 *Sci. Transl. Med.* **6**, 247ra102 (2014).
- 635 19. Reiling, L. *et al.* Targets of complement-fixing antibodies in protective immunity  
636 against malaria in children. *Nat. Commun.* **10**, 1–13 (2019).
- 637 20. Biggs, B. A., Kemp, D. J. & Brown, G. V. Subtelomeric chromosome deletions in field  
638 isolates of Plasmodium falciparum and their relationship to loss of cytoadherence in  
639 vitro. *Proc. Natl. Acad. Sci. U. S. A.* **86**, 2428–2432 (1989).
- 640 21. Kumar, S. *et al.* Distinct genomic architecture of Plasmodium falciparum populations  
641 from South Asia. *Mol. Biochem. Parasitol.* **210**, 1–4 (2016).
- 642 22. Miotto, O. *et al.* Multiple populations of artemisinin-resistant Plasmodium falciparum  
643 in Cambodia. *Nat. Genet.* **45**, 648–655 (2013).
- 644 23. Kapulu, M. C. *et al.* Controlled human malaria infection in semi-immune Kenyan  
645 adults (Chmi-sika): A study protocol to investigate in vivo plasmodium falciparum  
646 malaria parasite growth in the context of pre-existing immunity [version 2; peer  
647 review: 2 approved]. *Wellcome Open Res.* **3**, (2019).
- 648 24. Kapulu, M. C. *et al.* Safety and PCR monitoring in 161 semi-immune Kenyan adults  
649 following controlled human malaria infection. *JCI insight* **6**, (2021).

- 650 25. Hothorn, T. & Zeileis, A. Generalized maximally selected statistics. *Biometrics* **64**,  
651 1263–1269 (2008).
- 652 26. Fowkes, F. J. I., Richards, J. S., Simpson, J. A. & Beeson, J. G. The relationship  
653 between anti-merozoite antibodies and incidence of *Plasmodium falciparum* malaria:  
654 A systematic review and meta-analysis. *PLoS Med.* **7**, e1000218 (2010).
- 655 27. Richards, J. S. *et al.* Identification and Prioritization of Merozoite Antigens as Targets  
656 of Protective Human Immunity to *Plasmodium falciparum* Malaria for Vaccine and  
657 Biomarker Development . *J. Immunol.* **191**, 795–809 (2013).
- 658 28. Rono, J. *et al.* Breadth of anti-merozoite antibody responses is associated with the  
659 genetic diversity of asymptomatic *plasmodium falciparum* infections and protection  
660 against clinical malaria. *Clin. Infect. Dis.* **57**, 1409–1416 (2013).
- 661 29. Osier, F. H. A. *a et al.* Breadth and magnitude of antibody responses to multiple  
662 *Plasmodium falciparum* merozoite antigens are associated with protection from  
663 clinical malaria. *Infect. Immun.* **76**, 2240–2248 (2008).
- 664 30. Murungi, L. M. *et al.* A threshold concentration of anti-merozoite antibodies is  
665 required for protection from clinical episodes of malaria. *Vaccine* **31**, 3936–3942  
666 (2013).
- 667 31. França, C. T. *et al.* Identification of Highly-Protective combinations of *plasmodium*  
668 *vivax* recombinant proteins for vaccine development. *Elife* **6**, 1–22 (2017).
- 669 32. Mensah-Brown, H. E. *et al.* Antibody Reactivity to Merozoite Antigens in Ghanaian  
670 Adults Correlates with Growth Inhibitory Activity against *Plasmodium falciparum* in  
671 Culture. *Open Forum Infect. Dis.* **6**, 1–10 (2019).
- 672 33. Bustamante, L. Y. *et al.* Synergistic malaria vaccine combinations identified by  
673 systematic antigen screening. *Proc. Natl. Acad. Sci. U. S. A.* **114**, 12045–12050 (2017).
- 674 34. Draper, S. J. *et al.* Recent advances in recombinant protein-based malaria vaccines.  
675 *Vaccine* **33**, 7433–7443 (2015).
- 676 35. Beeson, J. G. *et al.* Challenges and strategies for developing efficacious and long-  
677 lasting malaria vaccines. *Sci. Transl. Med.* **11**, (2019).
- 678 36. Boyle, M. J. *et al.* Sequential processing of merozoite surface proteins during and after  
679 erythrocyte invasion by *Plasmodium falciparum*. *Infect. Immun.* **82**, 924–936 (2014).
- 680 37. Raj, D. K. *et al.* Antibodies to PfSEA-1 block parasite egress from RBCs and protect  
681 against malaria infection. *Science (80-. )*. **344**, 871–877 (2014).
- 682 38. Cecile, C. *et al.* Basigin is a receptor essential for erythrocyte invasion. *Nature* **480**,  
683 534–537 (2012).
- 684 39. Dent, A. E. *et al.* Contrasting Patterns of Serologic and Functional Antibody Dynamics  
685 to *Plasmodium falciparum* Antigens in a Kenyan Birth Cohort. *Clin. Vaccine Immunol.*  
686 **23**, 104–116 (2016).
- 687 40. Muntasell, A. *et al.* Targeting NK-cell checkpoints for cancer immunotherapy. *Curr.*  
688 *Opin. Immunol.* **45**, 73–81 (2017).
- 689 41. Shimasaki, N., Jain, A. & Campana, D. NK cells for cancer immunotherapy. *Nat. Rev.*  
690 *Drug Discov.* **19**, 200–218 (2020).



- 691 42. Bryceson, Y. T., March, M. E., Ljunggren, H.-G. & Long, E. O. Synergy among  
692 receptors on resting NK cells for the activation of natural cytotoxicity and cytokine  
693 secretion. *Blood* **107**, 159–166 (2006).
- 694 43. Bangaru, S. *et al.* A multifunctional human monoclonal neutralizing antibody that  
695 targets a unique conserved epitope on influenza HA. *Nat. Commun.* **9**, 1–15 (2018).
- 696 44. Lee, W. S. *et al.* Anti-HIV-1 ADCC Antibodies following Latency Reversal and  
697 Treatment Interruption. *J. Virol.* **91**, (2017).
- 698 45. Margolis, D. M., Koup, R. A. & Ferrari, G. HIV antibodies for treatment of HIV  
699 infection. *Immunol. Rev.* **275**, 313–323 (2017).
- 700 46. Sherratt, S., Patel, A., Baker, D. A., Riley, E. M. & Goodier, M. R. Differential IL-18  
701 Dependence of Canonical and Adaptive NK Cells for Antibody Dependent Responses  
702 to *P. falciparum*. *Front. Immunol.* **11**, 1–13 (2020).
- 703 47. Damelang, T. *et al.* Antibody mediated activation of natural killer cells in malaria  
704 exposed pregnant women. *Sci. Rep.* **11**, 1–16 (2021).
- 705 48. Jegaskanda, S., Reading, P. C. & Kent, S. J. Influenza-Specific Antibody-Dependent  
706 Cellular Cytotoxicity: Toward a Universal Influenza Vaccine. *J. Immunol.* **8**, 1–13  
707 (2013).
- 708 49. Vanderven, H. A. *et al.* What Lies Beneath: Antibody Dependent Natural Killer Cell  
709 Activation by Antibodies to Internal Influenza Virus Proteins. *EBioMedicine* **8**, 277–  
710 290 (2016).
- 711 50. Kamuyu, G. *et al.* KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein  
712 Microarray to Facilitate Malaria Vaccine Candidate Prioritization. *Front. Immunol.* **9**,  
713 1–16 (2018).
- 714 51. Crompton, P. D. *et al.* A prospective analysis of the Ab response to Plasmodium  
715 falciparum before and after a malaria season by protein microarray. *Proc. Natl. Acad.*  
716 *Sci. U. S. A.* **107**, 6958–6963 (2010).
- 717 52. Remarque, E. J., Faber, B. W., Kocken, C. H. M. & Thomas, A. W. Apical membrane  
718 antigen 1: a malaria vaccine candidate in review. *Trends Parasitol.* **24**, 74–84 (2008).
- 719 53. Dent, A. E. *et al.* Plasmodium falciparum protein microarray antibody profiles  
720 correlate with protection from symptomatic malaria in Kenya. *J. Infect. Dis.* **212**,  
721 1429–1438 (2015).
- 722 54. Kapulu, M. C. *et al.* Naturally acquired immunity among Kenyan adults suppresses the  
723 West African <em>&P. falciparum</em> NF54 strain in controlled human  
724 malaria infection (CHMI). *medRxiv* 2020.08.11.20172411 (2020)  
725 doi:10.1101/2020.08.11.20172411.
- 726 55. Bejon, P. *et al.* A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9  
727 ME-TRAP and MVA ME-TRAP among Children in Kenya. *PLoS Clin. Trials* **1**, e29  
728 (2006).
- 729 56. Mwangi, T. W., Ross, A., Snow, R. W. & Marsh, K. Case definitions of clinical  
730 malaria under different transmission conditions in Kilifi District, Kenya. *J. Infect. Dis.*  
731 **191**, 1932–1939 (2005).

- 732 57. TAYLOR, T. E. *et al.* Intravenous immunoglobulin in the treatment of paediatric  
733 cerebral malaria. *Clin. Exp. Immunol.* **2**, 357–362 (2006).
- 734 58. Boyle, M. J. *et al.* Isolation of viable *Plasmodium falciparum* merozoites to define  
735 erythrocyte invasion events and advance vaccine and drug development. *Proc. Natl.*  
736 *Acad. Sci. U. S. A.* **107**, 14378–14383 (2010).
- 737 59. Murungi, L. M., Kimathi, R. K., Tuju, J., Kamuyu, G. & Osier, F. H. A. Serological  
738 profiling for malaria surveillance using a standard ELISA protocol. *Methods Mol. Biol.*  
739 **2013**, 83–90 (2019).
- 740



741